Shareholders meeting

Ref: Akums/Exchange/2026-27/32 July 10, 2026 To, To, The Listing Department The Listing Department National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, C-1, Block G, 25th Floor, New Trading Ring, Bandra Kurla Complex, Rotunda Building, Phiroze Jeejeebhoy Bandra (E), Mumbai – 400 051 Towers, Dalal Street, Mumbai – 400 001 Symbol: AKUMS Scrip Code: 544222 Sub: Proceedings of the 22nd Annual General Meeting of the Company Respected Sir/Ma’am, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, please find enclosed proceedings of the 22nd Annual General Meeting of Akums Drugs and Pharmaceuticals Limited (“the Company”) held through Video Conferencing ("VC”) / Other Audio Visual Means (“OAVM”) on Friday, July 10, 2026 at 11:00 A.M. (IST) and concluded at 11:56 AM (IST). A copy of this disclosure is being updated on website of the Company at www.akums.in This is for your information and records. Thanking you, For Akums Drugs and Pharmaceuticals Limited Dharamvir Malik Company Secretary & Compliance Officer Encl.: As above SUMMARY OF THE PROCEEDINGS OF THE 22ND ANNUAL GENERAL MEETING OF THE MEMBERS OF AKUMS DRUGS AND PHARMACEUTICALS LIMITED (“THE COMPANY”) HELD ON FRIDAY, JULY 10, 2026 The 22nd Annual General Meeting (“AGM”) of the Company was held on Friday, July 10, 2026 at 11:00 A.M. (IST) through Video Conferencing (“VC”) / Other Audio-Visual Means (“OAVM”), in accordance with the relevant Circulars issued by the Ministry of Corporate Affairs (“MCA”) and Securities Exchange Board of India (“SEBI”). Mr. Dharamvir Malik, Company Secretary & Compliance Officer welcomed the members, attending the 22nd AGM and briefed them on certain important points relating to participation and e-voting during the AGM and further informed that the Company has provided shareholders the facility to cast their vote through the e-voting system administered by NSDL. The Company Secretary informed the members that the Statutory Registers and other documents as required under the Companies Act, 2013 were available for inspection. Further, he informed that pursuant to Section 113 of the Companies Act, 2013, the Company has received resolutions from certain shareholders appointing their authorized representatives to join the AGM, holding approximately 6.85 crores Equity Shares, which represents 43.52% of the Company’s paid-up capital. Thereafter, the Company Secretary has requested Mr. Sandeep Jain, Managing Director of the Company, who was elected as the Chairman for this AGM by the members of the Board to took over and conduct the proceedings of the meeting. Mr. Sandeep Jain, Managing Director of the Company, chaired the meeting and welcomed the members to the 22nd AGM of the Company. Upon confirmation received from NSDL that the requisite quorum being present, the Chairman called the meeting to order. He welcomed the Directors and requested those, who joined through VC, to introduce themselves to the members. He also introduced Chief Financial Officer and Company Secretary of the Company, present in the AGM. The respective Chairpersons of the Nomination and Remuneration Committee, Audit Committee and Stakeholders Relationship Committee, were present at the AGM. The representatives of the Company’s Statutory Auditors and Secretarial Auditors were also present at the AGM through VC. The Chairman has addressed the members that F.Y. 2025-26 was a year of progress, resilience and strategic execution. Despite global economic uncertainties, pricing pressures in certain pharmaceutical segments and a dynamic business environment, your Company continued to strengthen its position as India's largest Contract Development and Manufacturing Organisation (CDMO) while taking decisive steps towards becoming a globally relevant pharmaceutical manufacturing partner. The Chairman brought into the notice of the members, the Financial Highlights of the Company for the F.Y. 2025-26, including the proposed dividend. The Chairman also explained about the strengths of the Company in the CDMO business and the Company’s international expansion strategy i.e. formation of Joint Venture Company with the Government of the Republic of Zambia, by which the Company will establish a pharmaceutical manufacturing facility in Lusaka, creating a strong manufacturing and contribution towards healthcare self-sufficiency in Southern Africa. The Chairman further informed the members that the Company has secured long-term European CDMO contract with a leading global pharmaceutical Company which shows the representation of the Company in manufacturing products on world-class standards, over the last two decades. He further stated that these opportunities are aspiring the Company to transform into a truly global CDMO organization with meaningful contributions in international markets, particularly in Europe and Africa, which will become important pillars of growth alongside India and in line for this, the Company has developed a pipeline of 10+ products for launching in Europe and are in the process of certifying up to 4 more plants with European accreditations. The Chairman further stated that the competitive advantage and centre for growth strategy of the Company is innovation and for this purpose, four (04) Research & Development (R&D) centres, supported by more than 370 scientists and researchers, are continuously developing differentiated formulations and advanced drug delivery platforms. Thereafter, the Chairman explained about the commitment of the Company towards sustainability, governance and compliances, long-term growth plans and priorities simultaneously considering the responsibility of the Company towards the society at the same time. In the closing remarks, the Chairman expressed his gratitude towards the shareholders, directors, customers, employees, suppliers, regulators, bankers and business partners and wishes them and their families a good health, happiness, and prosperity. The Company Secretary read out the following resolutions as set out in the Notice of the 22nd AGM: 1. To receive, consider and adopt (a) the audited standalone financial statements of the Company for the financial year ended on March 31, 2026 and the reports of the Board of Directors and Auditors thereon; and (b) the audited consolidated financial statements of the Company for the financial year ended on March 31, 2026 and the report of Auditors thereon. 2. To declare dividend on the equity shares of the Company for the financial year ended on March 31, 2026 3. To re-appoint Mr. Sanjay Sinha (DIN: 03627342) who retires by rotation as Director and being eligible, offers himself for re-appointment 4. To ratify the remuneration of Cost Auditors for the financial year 2026-27 5. To approve the revision in remuneration of Mr. Sanjeev Jain, Managing Director and Promoter of the Company 6. To approve the revision in remuneration of Mr. Sandeep Jain, Managing Director and Promoter of the Company Thereafter, the Company Secretary invited speaker shareholders who have pre-registered themselves to express their views, ask questions and offer their valuable comments. The Chairman suitably responded to all the questions raised by the members at the AGM. Thereafter, the Chairman has authorised the Company Secretary to conclude the AGM. The Company Secretary informed the members that the facility of voting on the NSDL platform will continue to be available for the next 30 minutes, for those members who have not casted their votes and the results of the e-voting conducted at the AGM, aggregated with the results of remote e-voting shall be announced within the time stipulated under the applicable laws; and the same will be intimated to the Stock Exchanges and will be uploaded on the website of the Company & NSDL. The Company Secretary thanked Chairman sir and all the members of the Company w [Showing first 8,000 characters — download PDF for full document]